Key stats
About Range Cancer Therapeutics ETF
Expense ratio
0.79%
Home page
Inception date
Oct 13, 2015
CNCR takes an approach to niche coverage within the healthcare sector. It provides equal-weighted exposure to companies that generate their revenue from oncology products or are in constant development and production of cancer therapeutic medicine. Cancer Therapeutics is a term used to refer to the wide range of treatments and interventions used to treat various kinds of cancer. Equal weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space. Prior to June 20, 2023, the fund tracked the Loncar Cancer Immunotherapy Index and traded under the name Loncar Cancer Immunotherapy ETF. Effective October 20, 2023, the Loncar China BioPharma ETF that traded under the symbol CHNA merged into CNCR, acquiring its assets and expanding the funds exposure to China. Before June 3, 2024, the fund's index name swapped Cancer for Oncology, keeping the strategy unchanged.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.32%
Health Technology96.32%
Health Services1.72%
Technology Services1.21%
Bonds, Cash & Other0.68%
Mutual fund0.76%
Cash−0.08%
Stock breakdown by region
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history